Lauxera Capital Partners

OrganOx Limited, founded in 2008 in Oxford, United Kingdom, specializes in developing devices for organ preservation and transplantation. The company's flagship product, Metra, is designed to store livers outside the body at normal body temperature, mimicking the human body's environment through continuous perfusion with oxygen-carrying red cells and nutrition. This technology aims to prevent organ deterioration by maintaining physiological conditions such as bile production, glucose metabolism, and pH levels. OrganOx focuses on research and development for liver testing and transplantation, providing solutions to preserve livers before transplantations.

Acandis GmbH is a manufacturer of medical devices focused on the treatment of neurovascular diseases. The company specializes in a range of products, including engineering stroke solutions, flow diverters, stent retrievers, embolization devices, acute stroke care solutions, thrombectomy tools, and percutaneous transluminal angioplasty (PTA) devices. Acandis aims to support neuroradiologists by providing innovative and user-oriented devices that address both technical and medical challenges. The company's commitment to understanding symptoms, diagnostics, and treatment options allows it to develop comprehensive solutions that enhance patient care in acute stroke scenarios.

Synovo Group specializes in providing digital services and software solutions tailored for medical transport professionals. The company focuses on facilitating the digital transition for businesses by offering a comprehensive suite of IT management services, including hosting, outsourcing, telecom, and cloud services. Synovo Group's offerings comply with HDS standards for health data hosting, ensuring secure management of sensitive information. Additionally, the company provides hardware and software sales, infrastructure hosting, and security consultancy to help organizations effectively manage their transportation facilities. Through these services, Synovo Group aims to enhance operational efficiency and support logistics within the medical transport sector.

Natural Cycles is a digital health company that provides a contraceptive app aimed at enhancing women's reproductive health. The app allows users to track their basal body temperature daily, using a specialized thermometer to input data. This information, combined with other relevant metrics, is analyzed through a proprietary algorithm to determine fertility status throughout the menstrual cycle. The app features a color-coded calendar that informs users about their fertile days, helping them decide when they can have unprotected sex. By offering a non-invasive, non-hormonal method of fertility tracking, Natural Cycles empowers women to take control of their reproductive health and make informed decisions about family planning.

BioLamina AB is a biotechnology company based in Sundbyberg, Sweden, founded in 2009. It specializes in the development, manufacture, marketing, and sale of laminin cell culture products that support advanced cell research. The company offers a range of defined human recombinant laminin matrices designed to facilitate the culture of stem cells and tissue-specific cells. These products are utilized in various applications, including human and mouse embryonic stem cell culturing, the creation of beta cell islets, and single cell culturing. By mimicking natural cell-specific matrix interactions, BioLamina's reagents enhance the functionality of primary cells and contribute to the development of clinically compliant cell therapies. The company has established a strategic collaboration with CEVEC Pharmaceuticals GmbH to further its research and product offerings.

OrganOx Limited, founded in 2008 in Oxford, United Kingdom, specializes in developing devices for organ preservation and transplantation. The company's flagship product, Metra, is designed to store livers outside the body at normal body temperature, mimicking the human body's environment through continuous perfusion with oxygen-carrying red cells and nutrition. This technology aims to prevent organ deterioration by maintaining physiological conditions such as bile production, glucose metabolism, and pH levels. OrganOx focuses on research and development for liver testing and transplantation, providing solutions to preserve livers before transplantations.

Matrix Requirements GmbH is a global software provider specializing in quality management solutions for innovative medical device companies. Their flagship products, MatrixALM and MatrixQMS, help streamline regulatory processes by integrating agile development with compliance requirements, ensuring product safety and quality throughout the lifecycle. The company is certified to EN ISO 13485:2016 and ISO/IEC 27001:2013 standards.

Veranex is a global service provider that specializes in the medical technology sector, offering comprehensive, technology-enabled solutions from concept to commercialization. The company focuses exclusively on various areas within medical technology, including medical devices, diagnostics, companion diagnostics, digital health, and drug delivery. Veranex provides a wide range of services, such as design and engineering, regulatory support, clinical trials, and market access, enabling clients to streamline their development processes. By addressing the entire clinical trial journey, Veranex helps clients accelerate their time to market, enhance market viability, manage development costs, and reduce associated risks.

Lifen, a 160-employee Paris-based startup, specializes in streamlining medical data communication. Founded in 2015, it has become France's leading MSSanté operator, serving over 600 healthcare establishments and facilitating monthly exchanges of 2 million medical documents among 240,000 doctors. Lifen's platform simplifies data sharing through secure email, reducing paper mail and automating communication mode identification. Recognized for its interoperability expertise, Lifen aims to develop a platform that eases integration and deployment of digital solutions in healthcare.

Groupe PSIH provides healthcare data hosting and management services for managing activities of hospitals.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

LUMICKS specializes in advanced technologies for studying biology and cancer at the single-molecule and single-cell levels. The company aims to bridge the gap between molecular structure and function, enabling researchers to gain insights into complex biological processes. LUMICKS' flagship products, the C-Trap Optical Tweezers and Fluorescence Microscopy, allow for real-time analysis of molecular interactions. Additionally, the z-Movi Cell Avidity Analyzer provides tools for measuring and selecting immune cells based on their interactions with target cells. By facilitating live measurement and imaging, LUMICKS' instruments support researchers in understanding the fundamental causes of diseases, including cancer, and contribute to drug optimization efforts.

Reapplix ApS is a research and development company based in Birkerod, Denmark, founded in 2008. The company specializes in identifying and isolating blood-derived proteins that enhance wound healing, specifically for patients with chronic wounds. Reapplix designs and manufactures a tissue regeneration device that offers biological treatment for diabetic foot ulcers. Its platform facilitates evidence-based biological wound therapy, utilizing the patient's own blood to provide autologous active cell therapy, thereby empowering hospitals to support patients in their healing processes.